Trial Profile
A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary) ; Limosilactobacillus reuteri (Primary)
- Indications Acute enterocolitis; Necrotising enterocolitis
- Focus Registrational; Therapeutic Use
- Acronyms Connection
- Sponsors Infant Bacterial Therapeutics
- 11 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 11 Apr 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jun 2024.
- 11 Apr 2024 Status changed from recruiting to active, no longer recruiting.